FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Keytruda Melanoma Combination Trial Met Endpoints

[ Price : $8.95]

Merck and Moderna say a Phase 3 trial of Keytruda and intismeran autogene met key endpoints as an adjuvant melanoma treatment.

Auriga Research CGMP Violations

[ Price : $8.95]

FDA warns Indias Auriga Research contract testing laboratory about CGMP violations in its testing of drugs for clients.

Cellular, Gene Therapy Product FAQs

[ Price : $8.95]

FDA publishes a guidance with frequently asked questions on the development of cellular and gene therapy products.

FDA Authorizes First Standalone Robotic Device for Blood Draws

[ Price : $8.95]

FDA grants Vitestro a de novo authorization for Aletta, the first standalone robotic device designed to draw blood from a patients...

Teva NDA for Tourette Syndrome Accepted for Review

[ Price : $8.95]

FDA accepts for review a Teva Pharmaceuticals NDA for ecopipam, indicated for treating pediatric patients with Tourette syndrome.

FDA Cites Neeyaan for Process Validation and Quality-System Failures

[ Price : $8.95]

FDA cites Neeyaan LLC for multiple GMP deficiencies, including the firms failure to validate drug manufacturing processes, conduct...

How Will FDA Regulate Vision Language Models?

[ Price : $8.95]

Mosaic Clinical Technologies petitions FDA to explain the regulatory principles it is applying to artificial intelligence vision l...

FDA Wants Feedback on Device GenAI Discussion Paper

[ Price : $8.95]

FDA asks for stakeholder responses to six discussion questions in a paper on regulating generative AI-enabled medical devices.

4 API Manufacturing Violations at Chinas Tianjin Kilo

[ Price : $8.95]

FDA warns Chinas Tianjin Kilo Pharmaceutical Sci-tech Co. about CGMP deviations the agency found in records it requested on the co...

CGMP Violations Found in Eugia Pharma Inspection

[ Price : $8.95]

FDA warns Indias Eugia Pharma about CGMP violations at its drug manufacturing facility in Kolthur Village.